Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.
Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Rong Guo(Sun Yat-sen University), Chong Zhong(Guangzhou University of Chinese Medicine), Yihong Ling(Sun Yat-sen University), Qiang Li(Chinese Academy of Sciences), Lie Zheng(Sun Yat-sen University), Mingrong Cao(First Affiliated Hospital of Jinan University), Wenping Lin(Sun Yat-sen University), Changzhen Shang(Sun Yat-sen University), Huakun Huang(Zhujiang Hospital), Wei Wei(Zhujiang Hospital), Rongce Zhao(Sun Yat-sen University), Zhixing Guo(Sun Yat-sen University), Yuhua Wen(Tongji University), Yuan Cheng(Zhujiang Hospital), Lianghe Lu(Sun Yat-sen University), Jingwen Zou(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Qiaoxuan Wang(Institute of Polymers)
Cited by 30
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216